Selected research
Industry Research
Human Cytomegalovirus Envelope Glycoprotein B Industry Research Report 2026
Market perspective
The global Human Cytomegalovirus Envelope Glycoprotein B market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Human Cytomegalovirus Envelope Glycoprotein B is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Human Cytomegalovirus Envelope Glycoprotein B is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Human Cytomegalovirus Envelope Glycoprotein B is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Human Cytomegalovirus Envelope Glycoprotein B include Vical Incorporated, VBI Vaccine Inc, Vakzine Projekt Management GmbH, Trellis Bioscience, Inc. and Astellas Pharma Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Human Cytomegalovirus Envelope Glycoprotein B market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Cytomegalovirus Envelope Glycoprotein B Market by Company
Vical Incorporated
VBI Vaccine Inc
Vakzine Projekt Management GmbH
Trellis Bioscience, Inc.
Astellas Pharma Inc.
Human Cytomegalovirus Envelope Glycoprotein B Segment by Type
CSJ-148
CyMVectin
PPCM
TRL-345
Cytomegalovirus Vaccine
Others
Human Cytomegalovirus Envelope Glycoprotein B Segment by Application
Infectious Disease
Women's Health
Oncology
Others
Human Cytomegalovirus Envelope Glycoprotein B Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Cytomegalovirus Envelope Glycoprotein B market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Cytomegalovirus Envelope Glycoprotein B and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Cytomegalovirus Envelope Glycoprotein B.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Human Cytomegalovirus Envelope Glycoprotein B manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Human Cytomegalovirus Envelope Glycoprotein B by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Human Cytomegalovirus Envelope Glycoprotein B in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CSJ-148
- CyMVectin
- PPCM
- TRL-345
- Cytomegalovirus Vaccine
- Others
Applications
- Infectious Disease
- Women's Health
- Oncology
- Others
Companies covered
- Vical Incorporated
- VBI Vaccine Inc
- Vakzine Projekt Management GmbH
- Trellis Bioscience, Inc.
- Astellas Pharma Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size (2021-2032)
- 2.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales (2021-2032)
- 2.2.3 Global Human Cytomegalovirus Envelope Glycoprotein B Market Average Price (2021-2032)
- 2.3 Human Cytomegalovirus Envelope Glycoprotein B by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 CSJ-148
- 2.3.3 CyMVectin
- 2.3.4 PPCM
- 2.3.5 TRL-345
- 2.3.6 Cytomegalovirus Vaccine
- 2.3.7 Others
- 2.4 Human Cytomegalovirus Envelope Glycoprotein B by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Infectious Disease
- 2.4.3 Women's Health
- 2.4.4 Oncology
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue of Manufacturers (2021-2026)
- 3.4 Global Human Cytomegalovirus Envelope Glycoprotein B Average Price by Manufacturers (2021-2026)
- 3.5 Global Human Cytomegalovirus Envelope Glycoprotein B Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Product Type & Application
- 3.8 Global Manufacturers of Human Cytomegalovirus Envelope Glycoprotein B, Established Date
- 3.9 Global Human Cytomegalovirus Envelope Glycoprotein B Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Vical Incorporated
- 4.1.1 Vical Incorporated Company Information
- 4.1.2 Vical Incorporated Business Overview
- 4.1.3 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Vical Incorporated Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
- 4.1.5 Vical Incorporated Recent Developments
- 4.2 VBI Vaccine Inc
- 4.2.1 VBI Vaccine Inc Company Information
- 4.2.2 VBI Vaccine Inc Business Overview
- 4.2.3 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 VBI Vaccine Inc Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
- 4.2.5 VBI Vaccine Inc Recent Developments
- 4.3 Vakzine Projekt Management GmbH
- 4.3.1 Vakzine Projekt Management GmbH Company Information
- 4.3.2 Vakzine Projekt Management GmbH Business Overview
- 4.3.3 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Vakzine Projekt Management GmbH Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
- 4.3.5 Vakzine Projekt Management GmbH Recent Developments
- 4.4 Trellis Bioscience, Inc.
- 4.4.1 Trellis Bioscience, Inc. Company Information
- 4.4.2 Trellis Bioscience, Inc. Business Overview
- 4.4.3 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Trellis Bioscience, Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
- 4.4.5 Trellis Bioscience, Inc. Recent Developments
- 4.5 Astellas Pharma Inc.
- 4.5.1 Astellas Pharma Inc. Company Information
- 4.5.2 Astellas Pharma Inc. Business Overview
- 4.5.3 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Astellas Pharma Inc. Human Cytomegalovirus Envelope Glycoprotein B Product Portfolio
- 4.5.5 Astellas Pharma Inc. Recent Developments
5 Global Human Cytomegalovirus Envelope Glycoprotein B Market Scenario by Region
- 5.1 Global Human Cytomegalovirus Envelope Glycoprotein B Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2021-2032
- 5.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2021-2026
- 5.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Region: 2027-2032
- 5.3 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2021-2032
- 5.3.1 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2021-2026
- 5.3.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Region: 2027-2032
- 5.4 North America Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
- 5.4.1 North America Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2032)
- 5.4.3 North America Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
- 5.5.1 Europe Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2032)
- 5.5.3 Europe Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
- 5.6.1 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
- 5.7.1 South America Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2032)
- 5.7.3 South America Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Human Cytomegalovirus Envelope Glycoprotein B Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2021-2032)
- 6.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Type (2021-2032)
- 6.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Type (2021-2032)
- 6.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Type (2021-2032)
- 6.3 Global Human Cytomegalovirus Envelope Glycoprotein B Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2021-2032)
- 7.1.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Human Cytomegalovirus Envelope Glycoprotein B Sales Market Share by Application (2021-2032)
- 7.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue by Application (2021-2032)
- 7.2.1 Global Human Cytomegalovirus Envelope Glycoprotein B Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Human Cytomegalovirus Envelope Glycoprotein B Revenue Market Share by Application (2021-2032)
- 7.3 Global Human Cytomegalovirus Envelope Glycoprotein B Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Human Cytomegalovirus Envelope Glycoprotein B Value Chain Analysis
- 8.1.1 Human Cytomegalovirus Envelope Glycoprotein B Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Human Cytomegalovirus Envelope Glycoprotein B Production Mode & Process
- 8.2 Human Cytomegalovirus Envelope Glycoprotein B Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Human Cytomegalovirus Envelope Glycoprotein B Distributors
- 8.2.3 Human Cytomegalovirus Envelope Glycoprotein B Customers
9 Global Human Cytomegalovirus Envelope Glycoprotein B Analyzing Market Dynamics
- 9.1 Human Cytomegalovirus Envelope Glycoprotein B Industry Trends
- 9.2 Human Cytomegalovirus Envelope Glycoprotein B Industry Drivers
- 9.3 Human Cytomegalovirus Envelope Glycoprotein B Industry Opportunities and Challenges
- 9.4 Human Cytomegalovirus Envelope Glycoprotein B Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst